WO2023170633 - USE OF MODIFIED CELLS OF LEUKEMIC ORIGIN AND PD-L1 ANTIBODY FOR ENHANCING THE EFFICACY OF CANCER CELL THERAPY
National phase entry is expected:
Publication Number
WO/2023/170633
Publication Date
14.09.2023
International Application No.
PCT/IB2023/052272
International Filing Date
09.03.2023
Title **
[English]
USE OF MODIFIED CELLS OF LEUKEMIC ORIGIN AND PD-L1 ANTIBODY FOR ENHANCING THE EFFICACY OF CANCER CELL THERAPY
[French]
UTILISATION DE CELLULES MODIFIÉES D'ORIGINE LEUCÉMIQUE ET D'ANTICORPS PD-L1 POUR AMÉLIORER L'EFFICACITÉ D'UNE THÉRAPIE CELLULAIRE DIRIGÉE CONTRE LE CANCER
Applicants **
MENDUS B.V.
Inventors
MANTING, Erik Hans
SINGH, Satwinder
KARLSSON-PARRA, Alex
ZUO, Haoxiao
Priority Data
63/318,484
10.03.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3236 | |
| EPO | Filing, Examination, Granting | 31386 | |
| Japan | Filing, Examination, Granting | 3359 | |
| South Korea | Filing, Examination, Granting | 4523 | |
| USA | Filing, Examination, Granting | 13340 |
Total:
55,844
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Composition and methods for ex vivo expansion of natural killer (NK) cells, and methods for cell-based cancer immunotherapy are disclosed. Leukemic cell-derived dendritic cells and anti-PD-L1 antibodies, and certain embodiments with addition of PBMCs are used for in vivo administration for cancer treatment. Leukemic cell-derived dendritic cells and anti- PD-L1 antibodies are also used for ex vivo expansion of NK cells.[French]
Sont divulgués une composition et des procédés de multiplication ex vivo de cellules tueuses naturelles (NK), et des procédés d'immunothérapie anticancéreuse à base de cellules. Des cellules dendritiques dérivées de cellules leucémiques et des anticorps anti-PD-L1, certains modes de réalisation impliquant en outre l'ajout de PBMC, sont utilisés pour une administration in vivo pour le traitement du cancer. Des cellules dendritiques dérivées de cellules leucémiques et des anticorps anti-PD-L1 sont également utilisés pour la multiplication ex vivo de cellules NK.